Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13295

Full metadata record

DC Field	Value	Language
dc.contributor.author	Jadhav, Hemant R.	-
dc.date.accessioned	2023-12-01T06:25:07Z	-
dc.date.available	2023-12-01T06:25:07Z	-
dc.date.issued	2015	-
dc.identifier.uri	https://www.ingentaconnect.com/content/ben/mrmc/2015/00000015/00000002/art00005	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13295	-
dc.description.abstract	Rheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc. in treatment of RA, the high cost and associated immunological adverse effects have triggered discovery of small molecules targeting RA. This review describes the last 15 years of small molecular drug discovery in RA, focused mainly on preclinical and clinical studies	en_US
dc.language.iso	en	en_US
dc.publisher	Bentham Science	en_US
dc.subject	Pharmacy	en_US
dc.subject	Janus kinase	en_US
dc.subject	TNFα-converting enzyme	en_US
dc.subject	Tyrosine kinase inhibitors (TKIs)	en_US
dc.subject	Peptidyl arginine deiminase	en_US
dc.subject	Phosphoinositide 3-kinase	en_US
dc.subject	Rheumatoid arthritis	en_US
dc.title	Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Pharmacy

Files in This Item:

There are no files associated with this item.